1667-P: Mesenteric Visceral Lipectomy (MVL) Improves Glucose Tolerance in Patients with Type 2 Diabetes (T2D)

Aim: To evaluate the safety and metabolic effects of mesenteric visceral lipectomy in individuals with T2D. Methods & Study Design: Eight T2D subjects (age = 52±4 y; BMI = 34.1±1.0; stable diabetes meds/weight for 3 months) underwent pre-MVL assessment including OGTT, CGM, euglycemic insulin clamp with 3H-glucose, and MRI imaging. Repeat measurements were made at 6- and 12-months post-surgery. Exclusion criteria included prior insulin/TZD use. Insulin secretion [IS], Disposition Index [DI] and Matsuda index [MI] of insulin sensitivity were calculated with standard formulae. Results: At month 6, HbA1c decreased from 9.0% to 8.1% (p=0.08) and persisted at 8.4% at month 12 (p=0.19). CGM time-in-range increased significantly at 6 and 12 months (25% to 76%) (p